Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Key Inclusion Criteria:

• Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available
• Part B: Pancreatic Adenocarcinoma

• Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma
• Part B: NSCLC

• Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC
• Absence of known epidermal growth factor receptor (EGFR) mutation
• Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)
• Part B: Esophagogastric Adenocarcinoma:

• Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma
• Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)
• Part B: First-Line Colorectal Cancer

• Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum
• Radiographically measureable disease
• No prior cytotoxic chemotherapy to treat their metastatic disease
• Part B: Second-Line Colorectal Cancer

• Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum
• Radiographically measureable disease
• Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion
• Part B: Breast Cancer

• Histologically or cytologically confirmed metastatic breast cancer
• Radiographically measureable disease
• Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed
• Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician
• HER-2 negative tumor (primary tumor or metastatic lesion)
• Adequate organ function

Key Exclusion Criteria:

• Pregnant or lactating
• Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids
• Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months
• Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted

Note: Other protocol defined Inclusion/Exclusion criteria may apply.